Liddy, Nathaniel, Bossi, Giovanna, Adams, Katherine J., Lissina, Anna, Mahon, Tara M., Hassan, Namir J., Gavarret, Jessie, Bianchi, Frayne C., Pumphrey, Nicholas J., Ladell, Kristin Ingrid ![]() ![]() ![]() |
Abstract
T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a minority of patients with cancer. In the majority of these individuals, however, there is a failure of the specific T cell receptor (TCR)–mediated immune recognition and activation process. Here we describe the engineering and characterization of new reagents termed immune-mobilizing monoclonal TCRs against cancer (ImmTACs). Four such ImmTACs, each comprising a distinct tumor-associated epitope-specific monoclonal TCR with picomolar affinity fused to a humanized cluster of differentiation 3 (CD3)-specific single-chain antibody fragment (scFv), effectively redirected T cells to kill cancer cells expressing extremely low surface epitope densities. Furthermore, these reagents potently suppressed tumor growth in vivo. Thus, ImmTACs overcome immune tolerance to cancer and represent a new approach to tumor immunotherapy.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Systems Immunity Research Institute (SIURI) |
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
Publisher: | Nature Publishing Group |
ISSN: | 1078-8956 |
Date of Acceptance: | 17 October 2011 |
Last Modified: | 21 Oct 2022 10:52 |
URI: | https://orca.cardiff.ac.uk/id/eprint/41572 |
Citation Data
Cited 202 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |